The Stochastic Oscillator for MRSN moved out of overbought territory on September 20, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 51 similar instances where the indicator exited the overbought zone. In of the 51 cases the stock moved lower. This puts the odds of a downward move at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRSN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRSN broke above its upper Bollinger Band on September 13, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRSN's RSI Indicator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 06, 2023. You may want to consider a long position or call options on MRSN as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSN advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.704) is normal, around the industry mean (22.685). P/E Ratio (0.000) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (3.460) is also within normal values, averaging (316.663).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRSN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of antibody drug conjugates to improve patient outcomes in multiple oncology indications
A.I.dvisor indicates that over the last year, MRSN has been loosely correlated with MDGL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MRSN jumps, then MDGL could also see price increases.